Analyzing ZEALAND PHARMA/S (ZEAL) and RegeneRx Biopharmaceuticals (RGRX)

ZEALAND PHARMA/S (NASDAQ:ZEAL) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares ZEALAND PHARMA/S and RegeneRx Biopharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ZEALAND PHARMA/S -483.00% -78.33% -55.51%
RegeneRx Biopharmaceuticals -888.89% N/A -106.67%



Institutional & Insider Ownership

10.8% of ZEALAND PHARMA/S shares are owned by institutional investors. Comparatively, 0.1% of RegeneRx Biopharmaceuticals shares are owned by institutional investors. 10.9% of RegeneRx Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

ZEALAND PHARMA/S has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, RegeneRx Biopharmaceuticals has a beta of -2.15, suggesting that its stock price is 315% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for ZEALAND PHARMA/S and RegeneRx Biopharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZEALAND PHARMA/S 0 0 3 0 3.00
RegeneRx Biopharmaceuticals 0 0 1 0 3.00

ZEALAND PHARMA/S presently has a consensus price target of $29.00, suggesting a potential upside of 141.47%. RegeneRx Biopharmaceuticals has a consensus price target of $1.50, suggesting a potential upside of 733.80%. Given RegeneRx Biopharmaceuticals’ higher probable upside, analysts clearly believe RegeneRx Biopharmaceuticals is more favorable than ZEALAND PHARMA/S.

Valuation & Earnings

This table compares ZEALAND PHARMA/S and RegeneRx Biopharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ZEALAND PHARMA/S $21.23 million 17.40 -$41.35 million ($1.48) -8.11
RegeneRx Biopharmaceuticals $60,000.00 385.08 $280,000.00 N/A N/A

RegeneRx Biopharmaceuticals has lower revenue, but higher earnings than ZEALAND PHARMA/S.

Summary

ZEALAND PHARMA/S beats RegeneRx Biopharmaceuticals on 6 of the 11 factors compared between the two stocks.

ZEALAND PHARMA/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

RegeneRx Biopharmaceuticals Company Profile

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 (Tß4), for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply